Chief executive of (), Manuel Llobet, said maintaining double digit growth in the first half for consecutive years “demonstrates our robust business model.”
“We are outperforming our competitors and we are taking market share,” he added, as the firm gave an upbeat assessment of current trading.
It expects revenues to be in the order of £31.5mln in the first half of its financial year, which equates to a 12% rise at constant currencies.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE